Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer ...

In patients with bladder cancer, lactylation score may predict survival and efficacy of immune checkpoint inhibitor treatment, according to researchers.

Scotiabank initiated coverage of CG Oncology (CGON) with a Sector Perform rating and $23 price target The company is developing a novel ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

The first targeted treatment for the most common form of bladder cancer has been given the green light for NHS use. The recommendation on erdafitinib by the National Institute of Health and Care ...

A groundbreaking targeted treatment for the most common type of bladder cancer has been approved for use by the NHS, offering new hope to hundreds of patients. The National Institute of Health and ...

The first targeted treatment for the most common form of bladder cancer has been approved for NHS use. The National Institute of Health and Care Excellence (Nice) has given the go-ahead to ...

Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection Somatic pathogenic genomic alterations in patients with SCBC, UC, and SCLC of any ...

CG Oncology’s primary focus has been on advancing Creto through ... Targeted approach: The specificity of oncolytic viruses in targeting cancer cells while sparing healthy tissue could potentially ...